Future oncology最新文献

{"title":"The ongoing first-line treatment race for metastatic pancreatic ductal adenocarcinomas: will a tough disease lose its horror?","authors":"Wolfram C M Dempke, Christoph Sippel, Klaus Fenchel, Volker Heinemann, Eric van Cutsem, Dirk Arnold","doi":"10.1080/14796694.2026.2725499","DOIUrl":"10.1080/14796694.2026.2725499","url":null,"abstract":"<p><p>Pancreatic ductal adenocarcinomas (PDACs) are found to account for more than 5% of all cancer-related deaths worldwide. The 5-year survival rates are still low (<5% for in the metastatic setting). In patients with metastatic disease, combination chemotherapy regimens are currently standard of care. PDACs are K-RAS addicted (incidence >90%), however, RAS oncogenes have been regarded to be \"undruggable.\" Several highly specific inhibitors have been developed with atebimetinib (MEK inhibitor), daraxonrasib (tri-complex pan-K-RAS inhibitor), zoldonrasib (tri-complex K-RAS G12D inhibitor), INCB161734 (non-covalent ON/OFF inhibitor specific for K-RAS G12D), HRS-4642 (liposomal G12D inhibitor), and setidegrasib (G12D degrader) currently undergoing phase III evaluation in first-line PDACs. Five trials (RASolute-305 [zoldonrasib], DAWN-303 [INCB161734], MAPKeeper-301 [atebimetinib]), HRS-4642, and setidegrasib are comparing chemotherapy plus inhibitor with chemotherapy alone. In contrast, RASolute-303 (daraxonrasib) is a three-arms randomized trial with an additional arm being daraxonrasib monotherapy. Since the benefits provided by chemotherapy regimens are limited, it is conceivable that the novel targeted approaches may have the potential to overcome these limitations. Of note, outcomes for some of these compounds numerically exceeded the historical benchmarks with standard chemotherapy suggesting that a chemotherapy backbone might no longer be needed in the future.</p>","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"2603-2611"},"PeriodicalIF":3.1,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148839721","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"DESTINY-Lung06: trastuzumab deruxtecan and pembrolizumab as first-line treatment for HER2-overexpressing, PD-L1 TPS <50% NSCLC.","authors":"Pasi A Jänne, Cai-Cun Zhou, Egbert F Smit, Enriqueta Felip, George Blumenschein, Koichi Goto, William N William, Chihiro Abe, Jie Lin, Chun-Yen Cheng, Kaline Pereira","doi":"10.1080/14796694.2026.2724696","DOIUrl":"10.1080/14796694.2026.2724696","url":null,"abstract":"<p><p>Non-small cell lung cancer (NSCLC) that overexpresses human epidermal growth factor receptor 2 (HER2) is associated with poor prognosis, and no HER2-targeting therapies for HER2-overexpressing NSCLC are currently approved in the first-line setting. Pembrolizumab plus pemetrexed and platinum-based chemotherapy is a recommended first-line treatment option for nonsquamous NSCLC with no actionable genomic alterations. However, improved outcomes with pembrolizumab-based therapies correlate with higher programmed death-ligand 1 (PD-L1) levels, underscoring the need for more targeted treatment options for patients with lower PD-L1 tumor proportion scores (TPS; <50%). DESTINY-Lung06 is a multicenter, open-label, randomized, phase III trial evaluating the efficacy and safety of trastuzumab deruxtecan (T-DXd) in combination with pembrolizumab in the first-line setting in patients with HER2-overexpressing (≥25% moderate/strong membrane staining), PD-L1 TPS <50% NSCLC. Planned enrollment will be approximately 686 patients randomly assigned to either T-DXd 5.4 mg/kg with pembrolizumab 200 mg intravenously every 3 weeks (Q3W) or pembrolizumab 200 mg plus pemetrexed 500 mg/m² with platinum-based chemotherapy (cisplatin 75 mg/m² or carboplatin under the concentration-time curve 5 mg min/mL) intravenously Q3W. Progression-free survival by blinded independent central review and overall survival are the primary and key secondary endpoints of the study, respectively.<b>Clinical trial registration:</b> www.ClinicalTrials.gov identifier is NCT06899126; EudraCT identifier is 2024-515658-26-00.</p>","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"2559-2567"},"PeriodicalIF":3.1,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148873893","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Study protocol on quality of life and erectile function recovery in unfavorable intermediate-risk prostate cancer: REDI-CaP trial.","authors":"Rossella Di Franco, Simona Mercogliano, Rocco Mottareale, Valentina Borzillo, Esmeralda Scipilliti, Marcello Serra, Francesca Buonanno, Gianluca Ametrano, Francesco Perrone, Maria Carmela Piccirillo, Sandro Pignata, Sabrina Rossetti, Sisto Perdonà, Dario Franzese, Alessandro Izzo, Raffaele Muscariello, Giovanni Grimaldi, Luigi Castaldo, Secondo Lastoria, Francesca Di Gennaro, Marco Raddi, Antonella Petrillo, Igino Simonetti, Ernesta Cavalcanti, Renato De Falco, Maria Antonietta di Franco, Piera Maiolino, Mena Ilaria Pagliuca, D'Aniello Roberta, Ravo Vincenzo","doi":"10.1080/14796694.2026.2723713","DOIUrl":"10.1080/14796694.2026.2723713","url":null,"abstract":"<p><p>In unfavorable intermediate-risk prostate cancer, radiotherapy plus androgen deprivation therapy (ADT) is standard, but GnRH agonists can cause testosterone flare and delayed hormonal recovery, negatively affecting erectile function (EF) and quality of life (QoL). Relugolix, an oral GnRH antagonist, enables rapid testosterone suppression and faster recovery after discontinuation. The REDI-CaP trial investigates whether combining Relugolix with high-precision stereotactic body radiotherapy (SBRT) aims to improve EF recovery while evaluating whether cancer control is maintained.REDI-CaP is a prospective, single-arm, single-center Phase II study enrolling 55 patients (accounting for an anticipated 10% attrition rate, to yield 50 evaluable patients for the primary analysis). Participants receive Relugolix 120 mg daily for 6 months (AIFA-approved off-label use). SBRT is delivered with the CyberKnife system (36.25 Gy in 5 fractions) during the fourth month of ADT. The primary endpoint is EF recovery 6 months after ADT cessation, defined as an IIEF-5 score >17 or an increase of ≥5 points from baseline. Secondary endpoints include biochemical progression-free survival, acute and late toxicity, and patient-reported outcomes.Approved by the Institutional Ethics Committee; conducted according to ICH-GCP and the Declaration of Helsinki.The REDI-CaP trial is designed to investigate whether integrating pharmacology with advanced radiotherapy can help preserve patients' quality of life while assessing cancer control outcomes.Clinical Trial Registration: www.clinicaltrials.gov identifier is NCT07302451 and EU CT 2025-521170-33-00.</p>","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"2551-2558"},"PeriodicalIF":3.1,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148827476","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Plasma ctDNA clinical utility in patients with advanced breast cancer beyond targeted therapy selection.","authors":"María Dolores Martín Rivas, Javier Pascual","doi":"10.1080/14796694.2026.2727260","DOIUrl":"10.1080/14796694.2026.2727260","url":null,"abstract":"","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"2487-2491"},"PeriodicalIF":3.1,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149136276","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A study to learn how well HER3-DXd (patritumab deruxtecan) works and how safe it is in people with previously treated non-small-cell lung cancer that has a mutation in the EGFR gene: a plain language summary of the HERTHENA-Lung01 study.","authors":"Helena A Yu, Yasushi Goto, Pasi A Jänne","doi":"10.1080/14796694.2026.2691681","DOIUrl":"10.1080/14796694.2026.2691681","url":null,"abstract":"","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"2505-2520"},"PeriodicalIF":3.1,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13685561/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149166114","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"First-line management of unresectable hepatocellular carcinoma: clinical perspectives from the CheckMate 9DW study.","authors":"Bruno Sangro, Peter Galle, David Tai, Thomas Yau","doi":"10.1080/14796694.2026.2726118","DOIUrl":"10.1080/14796694.2026.2726118","url":null,"abstract":"<p><p>In this podcast, over a series of four parts, the authors provide an overview of the CheckMate 9DW study (NCT04039607) in hepatocellular carcinoma (HCC) and their opinions on how it impacts the treatment landscape for first-line unresectable HCC. The first two parts provide an overview of the primary safety and efficacy data from CheckMate 9DW as well as key sub-group analyses and additional findings. The third part focuses on the early crossing phenomenon of the overall survival Kaplan-Meier (KM) curves and discussion of potential contributors. The fourth part discusses the management of adverse events, the timing of immune‑mediated adverse events, and the impact of discontinuation and steroid use on efficacy. Across all parts, implications for clinical practice will be discussed, including topics such as patient selection, sequencing of therapies, immune-mediated toxicities, monitoring recommendations, and real-world considerations.</p>","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"2477-2486"},"PeriodicalIF":3.1,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149016789","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Treatment patterns after first-line abemaciclib therapy in patients with HR+, HER2- metastatic breast cancer in Japan.","authors":"Yoichi Naito, Tomoyuki Aruga, Yoshinori Tanizawa, Tomoko Terasawa, Tsutomu Kawaguchi, Toshimi Takano","doi":"10.1080/14796694.2026.2727324","DOIUrl":"10.1080/14796694.2026.2727324","url":null,"abstract":"<p><strong>Aims: </strong>To determine treatment patterns following first-line abemaciclib therapy in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+, HER2-) metastatic breast cancer in Japan.</p><p><strong>Methods: </strong>This retrospective observational study used a Japanese administrative claims database to identify patients with HR+, HER2- metastatic breast cancer who received first-line abemaciclib between November 2018 and March 2024. Patient characteristics and treatment patterns were summarized. Time to treatment discontinuation (TTD) was estimated by Kaplan-Meier analysis.</p><p><strong>Results: </strong>Among 3057 patients who received first-line abemaciclib, 520 received a second-line cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) (244 received abemaciclib and 276 received palbociclib) and 248 received endocrine monotherapy. Patients who received first-line abemaciclib plus a nonsteroidal aromatase inhibitor (NSAI) and second-line CDK4/6i had numerically longer median overall TTD (53.0 months) than those who received other second-line regimens (45.5 months). Patients who received first-line abemaciclib plus NSAI and second-line abemaciclib plus fulvestrant had numerically longer median second-line TTD (7.5 months) than those who received second-line fulvestrant monotherapy (4.0 months).</p><p><strong>Conclusions: </strong>Abemaciclib as both first- and second-line therapy was associated with sustained treatment duration in Japanese patients. Particularly, first-line abemaciclib plus NSAI followed by second-line abemaciclib plus fulvestrant may be a clinically meaningful treatment option.</p>","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"2569-2579"},"PeriodicalIF":3.1,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148944029","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Plain language summary of the long-term (5 or more years) outcomes in the CARTITUDE-1 trial of ciltacabtagene autoleucel in people with relapsed or refractory multiple myeloma.","authors":"Sundar Jagannath, Thomas G Martin, Yi Lin, Adam D Cohen, Noopur Raje, Myo Htut, Abhinav Deol, Mounzer Agha, Jesus G Berdeja, Alexander M Lesokhin, Jessica J Liegel, Adriana Rossi, Alex Lieberman-Cribbin, Saad Z Usmani, Binod Dhakal, Samir Parekh, Hui Li, Feng Wang, Rocio Montes de Oca, Vicki Plaks, Huabin Sun, Arnob Banerjee, Jordan M Schecter, Nikoletta Lendvai, Deepu Madduri, Tamar Lengil, Jieqing Zhu, Mythili Koneru, Muhammad Akram, Nitin Patel, Octavio Costa Filho, Andrzej J Jakubowiak, Peter M Voorhees","doi":"10.1080/14796694.2026.2720305","DOIUrl":"10.1080/14796694.2026.2720305","url":null,"abstract":"","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"2493-2504"},"PeriodicalIF":3.1,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149166874","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Infections in MonumenTAL-1: a plain language summary of talquetamab treatment for relapsed/refractory multiple myeloma.","authors":"Carolina Schinke, Paula Rodríguez-Otero, Niels W C J van de Donk, Brea Lipe, Noa Lavi, Leo Rasche, Diana Cortes-Selva, Tara Masterson, Sheetal Khedkar, Jaszianne Tolbert, Colleen Kane, Ibrahim Saber, Christoph Heuck, Ajai Chari","doi":"10.1080/14796694.2026.2722559","DOIUrl":"10.1080/14796694.2026.2722559","url":null,"abstract":"","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"2521-2536"},"PeriodicalIF":3.1,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13685558/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149069320","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Neoadjuvant nedaplatin and paclitaxel regimen with concurrent radiotherapy for esophageal squamous cell carcinoma: a single-arm phase II clinical trial.","authors":"Ting Liu, Xiao Dan, Qing Li, Peipei Wang, Yueyun Chen, Jiangfang Tian, Zhen Lin, Yang Hu, Huashan Shi, Zhenyu Ding","doi":"10.1080/14796694.2026.2701490","DOIUrl":"10.1080/14796694.2026.2701490","url":null,"abstract":"<p><strong>Aims: </strong>To evaluate the efficacy and safety of neoadjuvant concurrent chemoradiotherapy (CCRT) utilizing nedaplatin and paclitaxel in patients with locally advanced esophageal squamous cell carcinoma (ESCC).</p><p><strong>Patients & methods: </strong>Locally advanced ESCC patients received two cycles of nedaplatin plus paclitaxel or albumin-bound paclitaxel with concurrent radiotherapy (41.4-50.4 Gy) as neoadjuvant treatment. Immunohistochemical profiling was performed on biopsies and surgical specimens. The primary endpoint was the pathological complete response (pCR) rate.</p><p><strong>Results: </strong>Among 49 enrolled patients, 33 underwent surgery, yielding a pCR rate of 30.3%. Overall survival was inferior in resected patients with positive postoperative lymph nodes (HR 3.92, 95% CI 1.30-11.80, <i>p</i> = 0.02, log-rank <i>p</i> = 0.009). Higher FOXP3 expression before (HR 0.14, 95% CI 0.02-1.26, <i>p</i> = 0.08, log-rank <i>p</i> = 0.041) and after (HR 0.23, 95% CI 0.07-0.84, <i>p </i>= 0.03, log-rank <i>p</i> = 0.015) treatment nominally contributed to favorable outcomes. Upregulated TIGIT post-treatment trended toward a poorer prognosis in this surgical cohort (HR 7.10, 95% CI 0.79-63.65, <i>p</i> = 0.08, log-rank <i>p</i> = 0.041).</p><p><strong>Conclusion: </strong>Neoadjuvant nedaplatin and paclitaxel-based CCRT demonstrates encouraging preliminary antitumor efficacy. Tumor microenvironment profiling highlights FOXP3 and TIGIT dynamics as potential prognostic indicators. These hypothesis-generating insights warrant further validation in large-scale, randomized controlled trials. Clinical trial registration: Chinese Clinical Trial Registry (http://www.chictr.org.cn), identifier is ChiCTR1900024628. Date of registration: 19 July 2019.</p>","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"2189-2200"},"PeriodicalIF":3.1,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13432914/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148436373","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}